MedPath

Rivastigmine

Generic Name
Rivastigmine
Brand Names
Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis
Drug Type
Small Molecule
Chemical Formula
C14H22N2O2
CAS Number
123441-03-2
Unique Ingredient Identifier
PKI06M3IW0
Background

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Indication

For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Associated Conditions
Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease
Clinical Trials
Related News

Rivastigmine in the Management of Delirium

Phase 3
Completed
Conditions
Delirium
Interventions
Drug: placebo patch
First Posted Date
2011-12-07
Last Posted Date
2016-07-20
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
23
Registration Number
NCT01487317
Locations
🇫🇷

Pitié Salpetriere Hospital, Paris, France

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Phase 3
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo to Rivastigmine capsules
Drug: Placebo to Rivastigmine patch
First Posted Date
2011-07-21
Last Posted Date
2014-08-04
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
501
Registration Number
NCT01399125
Locations
🇨🇳

Novartis Investigative Site, Shanghai, China

Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

Not Applicable
Completed
Conditions
Alzheimer's Disease
Interventions
First Posted Date
2011-06-27
Last Posted Date
2018-02-05
Lead Sponsor
Dong-A University
Target Recruit Count
300
Registration Number
NCT01380288
Locations
🇰🇷

Busan National University Hospital, Busan, Korea, Republic of

🇰🇷

Kyungpook National University School of Medicine, Daegu, Korea, Republic of

🇰🇷

Myongji Hospital, Kwandong University College of Medicine, Goyang, Korea, Republic of

and more 13 locations

Comparative Research of Alzheimer's Disease Drugs

Not Applicable
Terminated
Conditions
Alzheimer's Disease
Dementia
Interventions
First Posted Date
2011-05-30
Last Posted Date
2017-02-27
Lead Sponsor
Indiana University
Target Recruit Count
200
Registration Number
NCT01362686
Locations
🇺🇸

Touchpoint, Fishers, Indiana, United States

🇺🇸

Methodist Center for Geriatric Medicine, Indianapolis, Indiana, United States

🇺🇸

University Clinical Neurology, Indianapolis, Indiana, United States

and more 2 locations

Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study

Phase 4
Completed
Conditions
Neurocognitive Disturbance
HIV Infection
Interventions
First Posted Date
2011-05-05
Last Posted Date
2014-04-01
Lead Sponsor
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Target Recruit Count
33
Registration Number
NCT01348282
Locations
🇪🇸

Fundació LLuita contra la SIDA, Badalona, Barcelona, Spain

Cognitive Decline in Non-demented PD

Phase 4
Completed
Conditions
Parkinson's Disease
Interventions
Other: Placebo
First Posted Date
2011-04-25
Last Posted Date
2020-07-07
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
9
Registration Number
NCT01340885
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

Completed
Conditions
Alzheimer's Disease
First Posted Date
2011-03-10
Last Posted Date
2016-05-04
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
300
Registration Number
NCT01312363
Locations
🇰🇷

Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of

🇰🇷

Yong-in Hyoja Geriatric Hospital, Yongin-si, Gyeonggi-do, Korea, Republic of

🇰🇷

Hanyang University Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of

and more 16 locations

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients

Phase 3
Completed
Conditions
Alzheimer Disease
Interventions
Other: Exercise training program
First Posted Date
2010-08-18
Last Posted Date
2012-03-20
Lead Sponsor
Federal University of Bahia
Target Recruit Count
40
Registration Number
NCT01183806
Locations
🇧🇷

Ferderal University of Bahia - DINEP, Salvador, Bahia, Brazil

🇧🇷

Federal University of Bahia, Salvador, Bahia, Brazil

Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-06-17
Last Posted Date
2012-01-13
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
44
Registration Number
NCT01146067

Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-06-17
Last Posted Date
2010-06-17
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
44
Registration Number
NCT01146041
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy